HB2114, the Block Organ Transplant Purchases from China Act of 2025, would prohibit federal health programs and private health coverage from paying for or covering certain organ transplants that have specified connections to the People’s Republic of China. The bill defines a “prohibited organ transplant” to include a transplant performed in China or a transplant involving an organ not procured through the U.S. Organ Procurement and Transplantation Network. It also bars payment or coverage for related follow-up care, tests, and drugs, except when such services are needed to save the patient’s life after the transplant.
The bill amends Medicare, Medicaid, and the Public Health Service Act to make these transplant-related services noncovered beginning January 1, 2026. It also adds a new section to the National Organ Transplant Act creating a direct federal prohibition on health care providers furnishing these transplants or related services, with criminal penalties for knowing violations and civil penalties enforceable by the U.S. Attorney General or state attorneys general. The Secretary of Health and Human Services would be required to issue implementing rules by January 1, 2026, including rules identifying prohibited items and services and calculating civil penalties.
In practical terms, the bill would affect hospitals, transplant centers, physicians, insurers, Medicare, Medicaid, and patients seeking organ transplants with the covered China-related connections. It would also expand federal oversight of transplant sourcing and payment rules, and it would create a new statutory basis for enforcement against providers who participate in the prohibited procedures. The bill’s definitions are broad, covering multiple organs and tissue types, including fetal-derived subparts and vascularized composite allografts.
No committee transcripts or recorded votes were provided, so there is no documented floor or committee sentiment in the available materials. Based on the bill text and sponsorship, the measure appears to be driven by concern over organ procurement practices in China and the desire to prevent U.S. participation in potentially abusive or unethical transplant activity. The absence of debate records means there is no direct evidence here of support or opposition from members beyond the bill’s introduction and referral.
The main point of contention is likely to be the breadth and enforceability of the prohibition, especially the definition of a prohibited transplant and the inclusion of any organ not procured through the U.S. transplant network. Critics could argue the bill may be overinclusive, difficult to administer, or could affect patients who need urgent care, while supporters would likely emphasize human rights, anti-trafficking, and ethical sourcing concerns. The criminal and civil penalty provisions, along with state attorney general enforcement authority, also suggest potential debate over federalism and provider liability.
The bill would amend Medicare, Medicaid, the Public Health Service Act, and the National Organ Transplant Act to bar payment, coverage, and provision of certain organ transplants tied to China or outside the U.S. transplant network. It would create new federal prohibitions, penalties, and enforcement mechanisms, and require HHS rulemaking to implement the restrictions starting in 2026.
No vote history or committee discussion was provided, so there is no recorded legislative sentiment to summarize from debate or roll call. The bill’s title and structure indicate a strongly restrictive, anti-China posture focused on preventing U.S. involvement in suspect organ transplant practices, which suggests support from sponsors and likely concern from opponents about scope and implementation.
The most notable contention is the bill’s broad definition of a prohibited organ transplant, which includes procedures in China and transplants involving organs not procured through the U.S. Organ Procurement and Transplantation Network. Potential critics may question whether the rule is too sweeping, whether it could interfere with patient access to care, and whether the enforcement regime is workable. Supporters are likely to focus on human rights, ethical sourcing, and preventing U.S. funds or providers from enabling abusive transplant practices.